Search Results

Thermi®, an Almirall, S.A. company, today announced that it has received a notice of completion to a U.S. Food and Drug Administration (FDA) inquiry on products used in “vaginal rejuvenation” procedures.

Thermi RF treatments in Canada include market leaders ThermiTight®, ThermiSmooth® Face and ThermiRase®, providing significant versatility, value, and control to clinicians

Thermi, an Almirall company, has created an innovative medical exchange and clinical training platform to advance the science of temperature-controlled tissue heating technology and best practices. This includes the launch of thirty-six (36) National Centers of Excellence (COE) sites, Thermi P.R.E.P. National Academy Platform, and a newly organized Medical Affairs organization led by Dr. Tara Margarella.

New platform with patented technology optimizes delivery of temperature-controlled monopolar radiofrequency using continuous wave technology with next-generation intelligent auto-modulation algorithms to maximize consistency and control

ThermiGen, LLC announced that it has reached a settlement with Viveve Medical, Inc. to resolve the patent litigation that was filed in 2016 .

ThermiVa® improved atrophic vaginitis, laxity and sexual satisfaction; First data to show better blood flow, new collagen and nerve growth in intimate tissue